Clinical trial Recruiting at 1 site Interventional Ages 21 to 65

Abuse liability and use patterns of IQOS heated tobacco among adult smokers

Official title: Studying User Sensory Experiences and Smoking Behavior of IQOS Heated Tobacco Products to Improve Harm Reduction Among Adult Cigarette Smokers

Run by Ohio State University Comprehensive Cancer Center · NCT07688304 · Data updated 2026-11-12

The study tests how appealing and user-friendly IQOS heat sticks are for adults who smoke, and compares how people puff and use IQOS versus their usual cigarettes.

More Tobacco Use trials

Quick facts

Study typeInterventional
Ages21 Years to 65 Years
SexAll
Enrollment30 (estimated)
SponsorOhio State University Comprehensive Cancer Center
Academic / other
Locations1 site (Columbus, Ohio)
StatusRecruiting
StartedAugust 27, 2026
Main results expectedJuly 2027
Study endsOctober 2027
Registry record updatedAugust 31, 2026
Trial IDNCT07688304 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 21–65 who smoke at least 5 days per week and are willing to abstain from nicotine 12 hours before visits and bring their usual cigarette to study visits.

Probably not a fit

Individuals who do not smoke regularly or who use non-combustible nicotine products or who are pregnant may not benefit from or participate in the study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, two-arm laboratory study compares IQOS heated tobacco products to a usual brand cigarette in adults who smoke. Participants alternate 60-minute sessions using IQOS or their usual cigarette, depending on arm, to assess sensory effects and puffing behavior. Secondary aims explore how flavor and perceived harm influence use, and an exploratory objective looks at acute changes in pulmonary health after IQOS use. The trial is conducted at the Ohio State University Comprehensive Cancer Center with collaboration from the NCI, and includes English-speaking adults 21–65 who smoke regularly. Ad lib use is permitted during laboratory sessions, with abstinence required 12 hours before visits.

Why it matters

Potential benefit: If successful, the study could clarify whether IQOS has appealing sensory effects and how it affects smoking behavior, informing risk-benefit considerations for smokers.

How similar studies have gone: Prior research has used similar lab-based comparisons of heated tobacco products and combusted cigarettes to characterize use and sensory responses, with mixed findings regarding abuse liability.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults 21-65 years
* Adults who smoke (defined as ≥ 5 days weekly use of either menthol or non-menthol cigarettes over the past 3 months)
* Willing to provide informed consent and abstain from using nicotine products 12 hours before each visit
* Willing to bring UBC to each study visit
* Read, write and speak English

Exclusion Criteria:

* Current use of other non-combustible nicotine products (e.g., electronic \[e\]-cigarettes, HTPs; \[defined as ≥ 5 days weekly use in the past 30 days\])
* Planning to quit nicotine use and/or use of any smoking cessation medication in the past 30 days
* Current diagnosis of any lung diseases (e.g., asthma, cystic fibrosis, or chronic obstructive pulmonary disease)
* Self-reported unstable or significant psychiatric conditions (past/stable conditions will be allowed)
* History of cardiac event or distress within the past 3 months
* Deaf, hard of hearing, or have a severe motor disability
* Are currently pregnant, planning to become pregnant, or breastfeeding (urine pregnancy test will be completed at each visit throughout the study)

Where it's running

  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio, United States
    Recruiting

Study contacts

  • Principal investigator: Alayna P Tackett, PhD — Ohio State University Comprehensive Cancer Center
  • Study coordinator: The Ohio State University Comprehensive Cancer Center
  • Email: OSUCCCClinicaltrials@osumc.edu
  • Phone: 800-293-5066

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.